Teva Pharmaceutical Industries plans to advance its investigational anti-interleukin-15 (IL-15) antibody, TEV-408, into a Phase 2b clinical trial for vitiligo following results from an ongoing Phase 1b study.
The Phase 1b trial, an open-label study in adults with active or stable non-segmental vitiligo, showed improvements in skin pigmentation and a favorable safety profile, with no safety signals reported to date. The company said the Phase 2b study is expected to begin in the fourth quarter of 2026.
Among evaluable participants at 24 weeks, nearly 75% reported improvement in facial vitiligo, with about half describing their condition as “much” or “very much” improved. Clinical measures showed that 42% of patients achieved at least a 50% improvement in the Facial Vitiligo Area Scoring Index (F-VASI50), while 21% reached F-VASI75. Improvements in total body vitiligo were reported by 55% of participants, with 7% achieving T-VASI50.
Most participants in the study had more extensive disease at baseline, with approximately two-thirds exhibiting vitiligo across more than 10% of body surface area.
TEV-408 targets IL-15, a cytokine implicated in the autoimmune processes underlying vitiligo. The antibody is being developed as a subcutaneous therapy with a proposed dosing interval of once every 12 weeks.
Vitiligo is a chronic autoimmune disorder characterized by loss of skin pigmentation and limited treatment options, particularly for patients requiring systemic therapy.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!